Effect of Co-administration of Ketoconazole on Attainment of Desired Blood Concentration of Tacrolimus in Renal Transplant Recipients Ketoconazole impact on tacrolimus in renal transplant
Iranian Journal of Pharmaceutical Sciences,
Vol. 21 No. 1 (2025),
21 Bahman 2025
,
Page 82- 88
https://doi.org/10.22037/ijps.v21i1.46021
Abstract
Achieving and maintaining optimal tacrolimus trough levels for immunosuppression is challenging in kidney transplant patients due to its narrow therapeutic index. Ketoconazole is known for inhibiting the drug efflux activity of P-glycoprotein and CYP3A enzymes, which are involved in tacrolimus pharmacokinetics. Therefore, there is a need to investigate tacrolimus–ketoconazole coadministration. The study aims to assess the effect and safety of tacrolimus-ketoconazole coadministration in renal transplant recipients. Ethical approval was obtained from the Institutional Human Ethics Committee (IHEC/2023/038) to conduct an ambispective observational study on 14 renal transplant recipients. Tacrolimus total daily dose (TDD) and trough levels were measured before and after initiating oral ketoconazole. The concentration/dose (C0/D) ratio was calculated, followed by safety assessments, including blood counts and renal function tests. Statistical analyses employed paired t-tests, and the significance level was <0.05. Coadministration resulted in a significant 102.45% increase in tacrolimus trough levels (p<0.001) and a 2.19% reduction (p=0.33) in TDD. The C0/D ratio showed a mean increase of 127.74%. Blood counts remained within normal ranges, but a significant decrease in sodium (p=0.01) and an increase in potassium (p=0.03) were observed within the normal range. Tacrolimus-ketoconazole co-administration in renal transplant recipients demonstrated a substantial elevation in tacrolimus trough levels, suggesting a potential strategy for achieving therapeutic concentrations without escalating tacrolimus doses. Despite significant changes in sodium and potassium, they remained within acceptable ranges, supporting the safety of this coadministration strategy.
- Tacrolimus
- ketoconazole
- Kidney transplantation
- Immunosuppressant
- Pharmacokinetics
How to Cite
References
Kasiske BL et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney international. 2010;77(4):299-311.
https://doi.org/10.1038/ki.2009.377
Neuwirt H, Rudnicki M, Schratzberger P, Pirklbauer M, Kronbichler A, Mayer G. Immunosuppression after renal transplantation. memo-Magazine of European Medical Oncology. 2019;12:216-221. https://doi.org/10.1007/s12254-019-0507-4
Bentata Y. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artificial organs. 2020;44(2):140-152. https://doi.org/10.1111/aor.13551
Christians U, Strom T, Zhang YL, Steudel W, Schmitz V, Trump S, Haschke M. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Therapeutic drug monitoring. 2006;28(1):039-044. https://doi.org/10.1097/01.ftd.0000183385.27394.e7
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clinical pharmacokinetics. 2004;43:623-653. https://doi.org/10.2165/00003088-200443100-00001
Andrews LM, Riva N, de Winter BC, Hesselink DA, de Wildt SN, Cransberg K, van Gelder T. Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. Expert opinion on drug metabolism & toxicology. 2015;11(6):921-936.
https://doi.org/10.1517/17425255.2015.1033397
Tuteja S, Alloway RR, Johnson JA, Gaber AO. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients1, 2. Transplantation. 2001;71(9):1303-1307. https://doi.org/10.1097/00007890-200105150-00021
Floren LC et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clinical Pharmacology & Therapeutics. 1997;62(1):41-49.
https://doi.org/10.1016/S0009-9236(97)90150-8
Fernandez PC, Wallace DW, Ryan K, Lin Q, Hollister AS. Effects of oral ketoconazole on renal function in healthy volunteers. Clinical Pharmacology & Therapeutics. 2005;77(2):81.https://doi.org/10.1016/j.clpt.2004.12.202
Bonhomme-Faivre L, Forestier F, Auchere D, Soursac M, Orbach-Arbouys S, Farinotti R. Chronic administration of verapamil, ketoconazole and carbamazepine: impact on immunological parameters. International journal of pharmaceutics. 2002;238(1-2):133-137. https://doi.org/10.1016/S0378-5173(02)00056-X
Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clinical Journal of the American Society of nephrology. 2007;2(2):374-384. https://doi.org/10.2215/CJN.03791106
Zhang X, Lin G, Tan L, Li J. Current progress of tacrolimus dosing in solid organ transplant recipients: pharmacogenetic considerations. Biomedicine & Pharmacotherapy. 2018;102:107-114.
https://doi.org/10.1016/j.biopha.2018.03.054
Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation. 1996 27;61(8):1268 -1272.
https://doi.org/10.1097/00007890-199604270-00026
Leather H, Boyette RM, Tian L, Wingard JR. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;12(3):325-334. https://doi.org/10.1016/j.bbmt.2005.10.022
Soltero L, Carbajal H, Rodriguez-Montalvo C, Valdés A. Coadministration of tacrolimus and ketoconazole in renal transplant recipients: Cost analysis and review of metabolic effects. InTransplantation proceedings 2003;35(4): 1319-1321.https://doi.org/10.1016/S0041-1345(03)00450-0
El-Dahshan KF, Bakr MA, Donia AF, Badr AE, Sobh MA. Ketoconazole-tacrolimus coadministration in kidney transplant recipients: two-year results of a prospective randomized study. American journal of nephrology. 2006;26(3):293-298. https://doi.org/10.1159/000094133
Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S. Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of oral solution itraconazole. International journal of hematology. 2009;90:103-107.
https://doi.org/10.1007/s12185-009-0344-z
Zhao YC et al. The Effect of Voriconazole on Tacrolimus in Kidney Transplantation Recipients: A Real-World Study. Pharmaceutics. 2022 7;14(12):2739. https://doi.org/10.3390/pharmaceutics14122739
Mori T et al. Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2012;95(5):564-569. https://doi.org/10.1007/s12185-012-1057-2
Lee CH, Kim GH. Electrolyte and acid-base disturbances induced by clacineurin inhibitors. Electrolytes & Blood Pressure: E & BP. 2007;5(2):126-30.
https://doi.org/10.5049/EBP.2007.5.2.126
Zhang S, Pillai VC, Mada SR, Strom S, Venkataramanan R. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica. 2012;42(5):409-416 https://doi.org/10.3109/00498254.2011.631224.
- Abstract Viewed: 383 times
- IJPS_Volume21_Issue1_Pages82-88 Downloaded: 413 times